Jonathan Wall is a tenured Professor at the University of Tennessee Medical Center, Knoxville, TN. He graduated from the University of Essex (Colchester, UK) with a baccalaureate in biological sciences and also received a PhD in Biological Chemistry and Biophysics for studies of protein-membrane interactions. He then joined the Human Immunology & Cancer Program at the University of Tennessee Medical Center, Knoxville as a post-doctoral fellow, where he worked on elucidating biochemical and biophysical aspects of immunoglobulin light chain amyloidosis. After moving to an Assistant Professorship, he helped establish a Preclinical Imaging Laboratory to study the biodistribution of amyloid-reactive antibodies, which resulted in a “first-in-human” PET/CT imaging trial of the 124I-11-1F4 therapeutic antibody (now CAEL-101) in patients with light chain-associated (AL) amyloidosis. He is now Professor and Director of the Amyloidosis and Cancer Theranostics Program at University of Tennessee
